Allergan will receive a CA$500,000 upfront payment from BLS which will be followed by subsequent additional payments based on net sales.
Valeant Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.
Valiant Pharmaceuticals CEO Michael Pearson said ACZONE Gel was a strong addition to their Canadian business.
"This compound was originally approved in 2006 and never launched into the Canadian marketplace, providing Valeant Canada with a unique opportunity to strengthen and enhance our dermatology portfolio in Canada," Pearson said.